AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8599314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 1580300 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Number of subjects: 0
Study 1580300 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable prognostic factors
Number of subjects: 0
Study 1580300 — intervention group
Group type: EXPERIMENTAL
Intervention: HER-2/neu oncogene overexpression
Number of subjects: 0
Study 1580300 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of low risk patients
Number of subjects: 0
Study 2856902 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg twice a day)
Number of subjects: 24
Study 2856902 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (40 mg twice a day)
Number of subjects: 24
Study 2856902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31113277 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate (mean dose: 622.0 mg/day)
Number of subjects: 97
Study 31113277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 30592848 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized food product based on fermented milk whey (1.2×10^8 CFU/cm3) consumed for 21 days
Number of subjects: 30
Study 30592848 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized food product based on fermented milk whey
Number of subjects: 30
Study 30592848 — intervention group
Group type: COMPARATOR
Intervention: Placebo (food starch of the same consistency)
Number of subjects: 30
Study 27065001 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg once daily (up-titrated to 50 mg/day after 4 weeks)
Number of subjects: 110
Study 27065001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 24766758 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced supervision (EAA; group plus individual)
Number of subjects: 82
Study 24766758 — intervention group
Group type: COMPARATOR
Intervention: Common practice approach (CPA; group only)
Number of subjects: 82
Study 24766758 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA and CPA peer counselors
Number of subjects: 82
Study 22476735 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea supplementation
Number of subjects: 0
Study 22476735 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrate inclusion
Number of subjects: 0
Study 22476735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugarcane cultivar IAC‐862480 (CC1)
Number of subjects: 0
Study 22476735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugarcane cultivar IAC‐873184 (CC2)
Number of subjects: 0
Study 20018326 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women (BMI ≥ 30 kg/m²) in SISTEr trial
Number of subjects: 1252
Study 20018326 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women (BMI ≥ 30 kg/m²) in TOMUS trial
Number of subjects: 1252
Study 20018326 — intervention group
Group type: COMPARATOR
Intervention: Normal and overweight women (BMI < 30 kg/m²) in both trials
Number of subjects: 1252
Study 17445921 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive corticosteroids (used by 109 patients, 58.9%)
Number of subjects: 185
Study 17445921 — intervention group
Group type: COMPARATOR
Intervention: Non-use of adjunctive corticosteroids
Number of subjects: 185
Study 15993028 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion axillary dissection (n=84)
Number of subjects: 165
Study 15993028 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary sample with at least four nodes (n=81)
Number of subjects: 165
Study 15993028 — intervention group
Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 165
Study 12021644 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital radiotherapy
Number of subjects: 0
Study 12021644 — intervention group
Group type: COMPARATOR
Intervention: Control group (internally controlled)
Number of subjects: 0
Study 10473741 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehension task
Number of subjects: 0
Study 10473741 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip opening
Number of subjects: 0
Study 10473741 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapping and bimanual movements
Number of subjects: 0
Study 10473741 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor function score (MOT)
Number of subjects: 0
Study 10473741 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural tests
Number of subjects: 0
Study 8732558 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 kcal/ounce premature infant formula with iron
Number of subjects: 43
Study 8732558 — intervention group
Group type: COMPARATOR
Intervention: 20 kcal/ounce standard cow's milk-based formula with iron
Number of subjects: 43
Study 8732558 — intervention group
Group type: COMPARATOR
Intervention: Mother's own milk with multivitamin supplement with iron
Number of subjects: 43
Study 1656730 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (enalapril)
Number of subjects: 14
Study 1656730 — intervention group
Group type: COMPARATOR
Intervention: Alpha 1-antagonist (prazosin)
Number of subjects: 14
Study 6613525 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-vinyl-GABA (GVG) 1 g per day
Number of subjects: 15
Study 6613525 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-vinyl-GABA (GVG) 2 g per day
Number of subjects: 15
Study 6613525 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-vinyl-GABA (GVG) 3 g per day
Number of subjects: 15
Study 6613525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29908417 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (NIL) 800 mg/day (Cohort 1)
Number of subjects: 108
Study 29908417 — intervention group
Group type: COMPARATOR
Intervention: High-dose imatinib (IM) 800 mg/day (Cohort 2)
Number of subjects: 108
Study 29908417 — intervention group
Group type: COMPARATOR
Intervention: Sustained standard-dose imatinib (IM) 400 mg/day (Cohort 3)
Number of subjects: 108
Study 27502710 — intervention group
Group type: COMPARATOR
Intervention: Standard paclitaxel at 200 mg/m(2) (arm A)
Number of subjects: 365
Study 27502710 — intervention group
Group type: EXPERIMENTAL
Intervention: PK-guided dosing of paclitaxel (arm B)
Number of subjects: 365
Study 24833327 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (NAC) 600 mg bid
Number of subjects: 120
Study 24833327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 22547125 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic single-piece IOL (ACR6D SE, Corneal, France)
Number of subjects: 50
Study 22547125 — intervention group
Group type: COMPARATOR
Intervention: Acrylic three-piece IOL (AF-1 UV, Hoya, Japan)
Number of subjects: 50
Study 22547125 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic single-piece IOL (ACR6D SE)
Number of subjects: 50
Study 22547125 — intervention group
Group type: COMPARATOR
Intervention: Acrylic three-piece IOL (AF-1 UV)
Number of subjects: 50
Study 20658823 — intervention group
Group type: EXPERIMENTAL
Intervention: computer-generated tailored letters
Number of subjects: 1097
Study 20658823 — intervention group
Group type: COMPARATOR
Intervention: assessment-only
Number of subjects: 1097
Study 18813043 — intervention group
Group type: COMPARATOR
Intervention: Low-dose dexmedetomidine (loading, 3 microg x kg(‐1) x h(‐1) for 10 min; maintenance, 0.2 microg x kg(‐1) x h(‐1) for 60 min)
Number of subjects: 14
Study 18813043 — intervention group
Group type: COMPARATOR
Intervention: High-dose dexmedetomidine (loading, 6 microg x kg(‐1) x h(‐1) for 10 min; maintenance, 0.4 microg x kg(‐1) x h(‐1) for 60 min)
Number of subjects: 14
Study 18813043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15860765 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-effects meta-analytic approach
Number of subjects: 0
Study 15860765 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporating external estimates of intraclass correlation
Number of subjects: 0
Study 11968583 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha monotherapy (3 million u. three times per week until signs of relapse)
Number of subjects: 83
Study 11968583 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence administration of interferon alpha and dexamethasone (40 mg on days 1-4, 10-13, and 20-23, followed by interferon alpha after a four-week interval until disease progression)
Number of subjects: 83
Study 11968583 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha monotherapy or dexamethasone (preference question)
Number of subjects: 83
Study 11968583 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment overall
Number of subjects: 83
Study 11968583 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment using EORTC QLQ-C30
Number of subjects: 83
Study 10662395 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 704
Study 10662395 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily
Number of subjects: 704
Study 10662395 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 704
Study 7776148 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal feedback of drinking relative to population norms
Number of subjects: 26
Study 7776148 — intervention group
Group type: COMPARATOR
Intervention: No personal feedback
Number of subjects: 26
Study 2181588 — intervention group
Group type: COMPARATOR
Intervention: Levodopa (mean dose: 485 ± 71 mg daily)
Number of subjects: 36
Study 2181588 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (mean dose: 55 ± 6 mg daily)
Number of subjects: 36
Study 394755 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline suppositories
Number of subjects: 9
Study 394755 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release aminophylline tablets
Number of subjects: 9
Study 394755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30821115 — intervention group
Group type: EXPERIMENTAL
Intervention: DP-VPA 1200 mg
Number of subjects: 12
Study 28376214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki‐67
Number of subjects: 263
Study 28376214 — intervention group
Group type: EXPERIMENTAL
Intervention: bcl2&bax
Number of subjects: 263
Study 28376214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki‐67 and bcl2&bax (jointly)
Number of subjects: 263
Study 28376214 — intervention group
Group type: COMPARATOR
Intervention: Base model
Number of subjects: 263
Study 25678838 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic only with lumbar interlaminar approach
Number of subjects: 240
Study 25678838 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic only with caudal approach
Number of subjects: 240
Study 25678838 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic with steroid with lumbar interlaminar approach
Number of subjects: 240
Study 25678838 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic with steroid with caudal approach
Number of subjects: 240
Study 23810548 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinsy tonsillectomy
Number of subjects: 34
Study 23810548 — intervention group
Group type: COMPARATOR
Intervention: Interval tonsillectomy
Number of subjects: 34
Study 21927793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 83
Study 21927793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 21927793 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide vs Placebo
Number of subjects: 83
Study 21927793 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in QLF
Number of subjects: 83
Study 20204991 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief self-management intervention emphasizing proactive coping
Number of subjects: 0
Study 20204991 — intervention group
Group type: COMPARATOR
Intervention: Usual-care controls
Number of subjects: 0
Study 17298590 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management-oriented programme (treatment B)
Number of subjects: 181
Study 17298590 — intervention group
Group type: COMPARATOR
Intervention: Didactic‐oriented training programme (treatment A)
Number of subjects: 181
Study 17298590 — intervention group
Group type: COMPARATOR
Intervention: More individualized approach (treatment C)
Number of subjects: 181
Study 15075997 — intervention group
Group type: EXPERIMENTAL
Intervention: Tannenbaum-type Teflon-coated stents (TTC)
Number of subjects: 60
Study 15075997 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene stents (PE)
Number of subjects: 60
Study 11233838 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (63 patients/95 hands) received 10 times 3 Gy (total: 30 Gy) in 2 series (each 5 times 3 Gy) separated by 8 weeks.
Number of subjects: 129
Study 11233838 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (66 patients/103 hands) received 7 times 3 Gy (total: 21 Gy) within 2 weeks.
Number of subjects: 129
Study 11233838 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 129
Study 11220982 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 10 mg
Number of subjects: 351
Study 11220982 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg
Number of subjects: 351
Study 11220982 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 351
Study 11220982 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (all doses combined)
Number of subjects: 351
Study 11220982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 8821690 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg every 28 days)
Number of subjects: 525
Study 8821690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (300 mg/day)
Number of subjects: 525
Study 8821690 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of goserelin acetate and cyproterone acetate
Number of subjects: 525
Study 8821690 — intervention group
Group type: COMPARATOR
Intervention: Control (monotherapy)
Number of subjects: 525
Study 1444298 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (100 mg twice a day for 10 days)
Number of subjects: 51
Study 1444298 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (500 mg four times a day for 10 days)
Number of subjects: 51
Study 1444298 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 51
Study 1444298 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 51
Study 6085231 — intervention group
Group type: EXPERIMENTAL
Intervention: PA 109
Number of subjects: 110
Study 6085231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 31821361 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/day)
Number of subjects: 18
Study 31821361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29074496 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary medical management
Number of subjects: 440
Study 29074496 — intervention group
Group type: COMPARATOR
Intervention: Augmented trabeculectomy
Number of subjects: 440
Study 26879791 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 790
Study 26879791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 790
Study 26879791 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Finasteride + Tamsulosin)
Number of subjects: 790
Study 26879791 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral 2 micron laser resection of the prostate
Number of subjects: 790
Study 26879791 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 790
Study 24659740 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) treatment
Number of subjects: 278
Study 24659740 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard chemotherapy)
Number of subjects: 278
Study 22167475 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐weighted sound pressure level
Number of subjects: 43
Study 22167475 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoacoustic loudness (5th percentile)
Number of subjects: 43
Study 22167475 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoacoustic annoyance (PA)
Number of subjects: 43
Study 20454855 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) d,l-MPH 20 mg
Number of subjects: 8
Study 20454855 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) d,l-MPH 20 mg
Number of subjects: 8
Study 17432644 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking combined with chiropractics
Number of subjects: 78
Study 17432644 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of pepsin mixture
Number of subjects: 78
Study 16130060 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (0.03 microg/kg/min)
Number of subjects: 0
Study 16130060 — intervention group
Group type: COMPARATOR
Intervention: Milrinone (50 microg/kg followed by 0.5 microg/kg/min)
Number of subjects: 0
Study 11851868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.2 mg daily for 6 weeks, then increased to 0.4 mg if LDL-C did not decrease below 3.0 mmol x L(-1))
Number of subjects: 38
Study 11851868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (250 mg daily)
Number of subjects: 38
Study 9861907 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention program (early surgery, minimal narcotic analgesia, intense daily therapy, close monitoring)
Number of subjects: 71
Study 9861907 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (routine hospital management)
Number of subjects: 71
Study 9861907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program
Number of subjects: 71
Study 9861907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 71
Study 7595907 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.8 mg daily for 7 days (short protocol)
Number of subjects: 16
Study 7595907 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone for 6 weeks (long protocol)
Number of subjects: 16
Study 7595907 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (1.4 nmol/l) in vitro
Number of subjects: 16
Study 7595907 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone treatment
Number of subjects: 16
Study 7595907 — intervention group
Group type: COMPARATOR
Intervention: Thrombin and vasopressin stimulation
Number of subjects: 16
Study 2082005 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 0
Study 2082005 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect (Korotkoff) method
Number of subjects: 0
Study 31684841 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 146
Study 31684841 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 146
Study 30897090 — intervention group
Group type: COMPARATOR
Intervention: Continue cotrimoxazole (CTX)
Number of subjects: 100
Study 30897090 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinue cotrimoxazole (STOP-CTX)
Number of subjects: 100
Study 28634728 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemon oil
Number of subjects: 30
Study 28634728 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil
Number of subjects: 30
Study 28634728 — intervention group
Group type: COMPARATOR
Intervention: Water (control stimulus)
Number of subjects: 30
Study 25466292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic compression belt (PCB)
Number of subjects: 50
Study 23576531 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese participants
Number of subjects: 20
Study 23576531 — intervention group
Group type: COMPARATOR
Intervention: Non-obese participants
Number of subjects: 20
Study 21118281 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg intravenously)
Number of subjects: 19
Study 21118281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 19489487 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Fenglong (ST 40) with parameters: 50 Hz, 1 mA for TG type (20 min, twice/week); 100 Hz, 1 mA for CHO type (30 min, thrice/week); same as CHO for LDL-C type; alternating methods for mixing type.
Number of subjects: 204
Study 19489487 — intervention group
Group type: COMPARATOR
Intervention: Xuezhikang capsule, 2 capsules twice daily for 11 weeks.
Number of subjects: 204
Study 16479346 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure hemorrhoidectomy with submucosal dissection
Number of subjects: 84
Study 16479346 — intervention group
Group type: COMPARATOR
Intervention: Ferguson hemorrhoidectomy
Number of subjects: 84
Study 14749658 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus resistance exercise
Number of subjects: 32
Study 14749658 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 32
Study 11322472 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training (15 sessions with handrail support)
Number of subjects: 25
Study 11322472 — intervention group
Group type: COMPARATOR
Intervention: Conventional over-ground gait training (15 sessions)
Number of subjects: 25
Study 9160363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingertip temperature monitoring during rewarming
Number of subjects: 14
Study 9160363 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal temperature monitoring during rewarming
Number of subjects: 14
Study 9160363 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial blood temperature monitoring during rewarming
Number of subjects: 14
Study 9160363 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall temperature monitoring during rewarming
Number of subjects: 14
Study 9160363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingertip temperature as a monitor for cerebral temperature
Number of subjects: 14
Study 9160363 — intervention group
Group type: EXPERIMENTAL
Intervention: Further body warming
Number of subjects: 14
Study 8192275 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 grams of oral vitamin C for one month
Number of subjects: 124
Study 3285763 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg)
Number of subjects: 16